Europe Pharmacovigilance and Drug Safety Software Market Size & Outlook, 2025-2033
Europe Pharmacovigilance and Drug Safety Software Market Insights
- As per Reed Intelligence insights, Europe’s Pharmacovigilance and Drug Safety Software Market was valued at USD 41.59 Million in 2024 and is anticipated to expand to USD 76.18 Million by 2033.
- From 2026 to 2033, the market is anticipated to expand at a CAGR of 6.87%.
- Within By Functionality, Case data collection and management accounted for the largest market size in 2024.
- During the forecast period, Case data collection and management is anticipated to remain the highest-growth segment within the By Functionality category.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Europe held 20.2% share of the global Pharmacovigilance and Drug Safety Software Market size in 2024.
- United States is expected to remain the largest contributor to the global market size by 2033.
- By 2033, Germany is anticipated to record the highest growth in Europe, with the market size expected to reach USD 19.25 Million.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 41.59 Million |
| Market Size In 2033 | USD 76.18 Million |
| Largest segment | Case data collection and management |
| Units | Revenue in USD Million |
| CAGR | 6.87% (2025-2033) |
| Segmnetation Covered | |
| Europe |
|
| By Functionality |
|
| By Delivery Mode |
|
| By End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Europe Pharmacovigilance and Drug Safety Software Market Country 2025-2033 (USD Million)
| Europe | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | XX.x | XX.x | XX.x | 10.4 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| United Kingdom | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| France | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Italy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Spain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Russia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nordic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Benelux | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Europe Pharmacovigilance and Drug Safety Software Market By Functionality 2025-2033 (USD Million)
| By Functionality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case data collection and management | XX.x | XX.x | XX.x | 20.86 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Adverse event reporting and analysis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Signal detection and other safety risk assessment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Europe Pharmacovigilance and Drug Safety Software Market By Delivery Mode 2025-2033 (USD Million)
| By Delivery Mode | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| On Premise | XX.x | XX.x | XX.x | 22.96 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| On Demand | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Europe Pharmacovigilance and Drug Safety Software Market By End Use 2025-2033 (USD Million)
| By End Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare Companies | XX.x | XX.x | XX.x | 20.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CROs/BPOs/PV service providers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
